WO1998031702A1 - 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives - Google Patents
16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives Download PDFInfo
- Publication number
- WO1998031702A1 WO1998031702A1 PCT/EP1998/000377 EP9800377W WO9831702A1 WO 1998031702 A1 WO1998031702 A1 WO 1998031702A1 EP 9800377 W EP9800377 W EP 9800377W WO 9831702 A1 WO9831702 A1 WO 9831702A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrogen
- pharmaceutically acceptable
- compound
- estra
- ealkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
- C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
- C07J1/0096—Alkynyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Definitions
- the present invention relates to certain 16-hydroxy-11 -(substituted phenyl)- estra- ,9-diene derivatives, to processes for their preparation, to pharmaceutical formulations containing them and to their use in medical therapy, in particular in the treatment or prophylaxis of glucocorticoid- dependent diseases.
- Ri is d-ealkyl, triflate, pyridyl or phenyl where the phenyl moiety is optionally substituted by one or more substituents selected from cyano, halogen and d ⁇ alkyl;
- R 2 is hydrogen, C h alky!, 1-oxo-C ⁇ alkyl or carboxy-1-oxo-C ⁇ alkyl;
- R 3 is hydrogen, halogen or d-ealkyl optionally substituted by one or more substituents selected from d-ealkoxy and halogen;
- R 4 is hydrogen, d-ealkyl, 1 -oxo-d-ealkyl or carboxy-l-oxo-d-ealkyl; and X is (H.OH), O or NOH; or a pharmaceutically acceptable salt or solvate thereof.
- the present invention includes the 16-hydroxy-11 -(substituted phenyl )-estra- 4,9-diene derivatives of formula I wherein:
- R 3 is hydrogen, halogen, for example, chloro, d-ealkyl, for example, methyl, ethyl, propyl or t-butyl optionally substituted by d- ⁇ alkoxy, such as methoxy.
- R 4 is hydrogen or methyl.
- X is O.
- Ri, R 2 , R3, 4 and X are as defined in points 1 to 5 supra or a pharmaceutically acceptable salt or solvate thereof.
- alkyl means a straight or branched chain alkyl group.
- alkyl groups include methyl, ethyl, i-propyl, n-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl and neohexyl.
- Reference to cycloalkyl includes cyclopropyl, cyclopentyl and cyclohexyl.
- alkoxy has the meaning as understood by the person skilled in the art and includes straight and branched chains. Examples of alkoxy groups include methoxy and ethoxy. Preferred alkoxy groups include d ⁇ alkoxy.
- 1-oxo-C ⁇ alkyl or carboxy-1 -oxo-d- ⁇ alkyl groups include 1-oxo-methyl, 1-oxo- ethyl, 1-oxo-propyl, 3-carboxy-1-oxopropyl, 3-carboxy-1-oxobutyl and 3-carboxy-1 -oxopentyl.
- Preferred examples of Ri are phenyl and C ⁇ -6alkyl, for example, t-butyl (1,1-dimethylethyl), isopropyl (1-methylethyl) or methyl, most preferably t-butyl and phenyl.
- R 2 is preferably hydrogen.
- R 3 include d-ealkyl, most preferably methyl.
- Preferred compounds of formula I include those wherein Ri is phenyl or for example, t-butyl, isopropyl or methyl; R 2 is hydrogen; Rs is Ci- ⁇ alkyI, most preferably methyl; R4 is hydrogen or d-ealkyl, in particular methyl; and X is O; or a pharmaceutically acceptable salt or solvate thereof.
- salts of the compounds of formula I are those wherein the counterion is pharmaceutically acceptable.
- salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
- the compounds of formula I and their pharmaceutically acceptable salts or solvates for use in therapy, more particularly in the treatment or prophylaxis of glucocorticoid dependent diseases or symptoms such as Cushing syndrome, diabetes, glaucoma, sleep disturbances, depression, anxiety, atherosclerosis, hypertension, adiposity, osteoporosis, addiction and the treatment of the symptoms of withdrawal from substance abuse, for example, narcotics, cocaine and alcohol.
- the compounds also find use in the treatment of neurodegenerative diseases, such as, Alzheimers and psychotic disorders such as schizophrenia, mania, hyperactivity, substance abuse, emesis and schizophreniaform disorders.
- the present invention further includes a method for the treatment of an animal, for example, a mammal including a human, suffering from or liable to suffer from a glucocorticoid dependent disease including any of the aforementioned diseases or symptoms, which comprises administering an effective amount of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof.
- the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment or prophylaxis of any of the aforementioned diseases or symptoms.
- the amount of a compound of formula I or a pharmaceutically acceptable salt or solvate, also referred to herein as the active ingredient, which is required to achieve a therapeutic effect will, of course, vary with the particular compound, the route of administration, the age and condition of the recipient, and the particular disorder or disease being treated.
- the present invention further provides a pharmaceutical formulation comprising a compound of formula I or a pharmaceutically acceptable salt or solvate thereof together with a pharmaceutically acceptable carrier thereof and optionally other therapeutic agents.
- the carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipients thereof.
- Formulations for rectal administration may be presented as a suppository or enema.
- suitable formulations include aqueous and non-aqueous sterile injection.
- the formulations may be presented in unit- dose or multi-dose containers, for example, sealed vials and ampoules, and may be stored in a freeze dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, water prior to use.
- Formulations suitable for administration by nasal inhalation include fine dusts or mists which may be generated by means of metered dose pressurised aerosols, nebulisers or insufflators.
- the present invention further includes the following processes for the preparation of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof.
- the compounds of formula I may be produced by various methods known in the art of organic chemistry in general. Starting materials are either known and readily available from chemical sources or may themselves be produced by conventional techniques.
- P is a protected keto group and R 5 is a group R 4 as defined in relation to formula I or a suitably protected R 4 group.
- Suitable protecting groups and methods to remove these groups are known in the art, for example from T.W. Green: Protective Groups in Organic Synthesis (Wiley, NY, 1981 ).
- Particularly suitable protecting groups for the protection of keto groups are acetals, for example, 1 ,2-ethylene ketal. Such groups may be removed, for example, by acid hydrolysis.
- compounds of formula I wherein X is NOH may be prepared by condensation of a compound of formula I wherein X is O with a suitable oximating agent.
- a suitable oximating agent such as pyridine.
- compounds of formula II may conveniently be prepared using estra-5(10),9(11)-diene-3,17-dione-3-(cyclic 1 ,2-ethanediyl acetal) as a starting material as herein before described.
- This compound may be converted into the corresponding 5 ⁇ 1 O ⁇ -epoxide e.g. with hydrogen peroxide, trifluoroacetophenone and pyridine in dichloromethane according to the procedure described in EP 0298020.
- a copper catalyzed Grignard reaction provides the corresponding 3-protected-11-aryl-5-hydroxy-estr-9,10- en-17-one.
- Compounds of formula I may be converted into a pharmaceutically acceptable 1 by reaction with an appropriate esterifying agent, for example, by treatment with an appropriately activated carboxylic acid, like for example an acid chloride, or an activated dicarboxylic acid, like for example a cyclic anhydride, using methods well known in the art.
- the compounds of formula I may be converted into pharmaceutically acceptable salts thereof in a conventional manner, for example by treatment with the appropriate acid.
- the present invention further includes all novel intermediates defined herein and in particular compounds of formula II.
- Particularly preferred intermediates include:
- a solution of 181 mmol LDA (prepared by adding 113 ml of a 1.6 M n-BuLi solution to a solution of 25.6 ml diisopropylamine in 400 ml dry THF) was added dropwise to a cold solution (-60 °C) of 28 g (60 mmol) 5 ⁇ -hydroxy-11 ⁇ - [4-t-butylphenyl]-estr-9-en-3-one 3-(cyclic 1 ,2-ethanediyl acetal) in 700 ml dry THF. Stirring was continued for 30 min at -50°C. Then 38.3 ml of thmethylsilylchloride was added dropwise and the solution was stirred at -45 °C for 1 hour.
- Methyllithium (11 ml 2.2 M solution in diethyl ether) was added dropwise at 0 °C to a solution of 1.2 g trans-1 ,2-dichloroethene (12 mmol) in 5 ml dry diethyl ether. Stirring was continued at room temperature for 1.5 hrs. Then, a solution of 1.4 g (3 mmol) 5 ⁇ ,16 ⁇ ,17 ⁇ -trihydroxy-11 ⁇ -[4-t-butylphenyl]-estr-9- ene-3,17-dione 3-(cyclic 1 ,2-ethanediyl acetal) dissolved in 20 ml dry toluene was added dropwise and stirring was continued for 1 hr at ambient temperature.
- the glucocorticoid affinity of the compounds was measured for glucocorticoid receptors present in intact human multiple myeloma cells and compared with the affinity of dexamethasone (according to the procedure described by H.J. Kloosterboer et al., J. Steroid Biochem., Vol. 31 , 567-571 (1988)).
- the progesterone affinity of the compounds was measured for cytoplasmic progesterone receptors present in human breast tumor cells and compared with the affinity of (16 ⁇ )-16-ethyl-21-hydroxy-19-no regn-4-en-3,20-dione (according to the procedure described by E.W. Bergink et al., J. Steroid Biochem., Vol. 19, 1563-1570 (1983)).
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9807079-7A BR9807079A (en) | 1997-01-15 | 1998-01-13 | Compound of 16-hydroxy-11- (substituted phenyl) - estrus-4,9-diene derivative, use of a compound, pharmaceutical formulation, and process for the preparation of a compound. |
JP53369598A JP2001508079A (en) | 1997-01-15 | 1998-01-13 | 16-hydroxy-11- (substituted phenyl) -estradi-4,9-diene derivatives |
PL98334518A PL334518A1 (en) | 1997-01-15 | 1998-01-13 | Derivatives of 16-hydroxy-11-(phenyl-substituted) -estra-4,9-diene- |
AU62935/98A AU736064B2 (en) | 1997-01-15 | 1998-01-13 | 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives |
EP98906887A EP0973792B1 (en) | 1997-01-15 | 1998-01-13 | 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives |
US09/341,603 US6072068A (en) | 1997-01-15 | 1998-01-13 | 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives |
CA002277924A CA2277924A1 (en) | 1997-01-15 | 1998-01-13 | 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives |
NZ336790A NZ336790A (en) | 1997-01-15 | 1998-01-13 | 16,17-dihydroxy-11-(substituted phenyl)-17-(1-propynyl)-estra-4,9-diene derivatives |
AT98906887T ATE248854T1 (en) | 1997-01-15 | 1998-01-13 | 16-HYDROXY-11-(SUBSTITUTED PHENYL)-ESTRA-4,9-DIENE DERIVATIVES |
DE69817792T DE69817792T2 (en) | 1997-01-15 | 1998-01-13 | 16-HYDROXY-11- (SUBSTITUTED PHENYL) -ESTRA-4,9-DIEN DERIVATIVES |
HU0000901A HUP0000901A3 (en) | 1997-01-15 | 1998-01-13 | 16-hydroxy-11(substituted phenyl)-estra-4,9-diene derivatives, process for their preparation and pharmaceutical compositions containing them |
NO19993459A NO313386B1 (en) | 1997-01-15 | 1999-07-14 | 16-Hydroxy-11- (substituted phenyl) -estra-4,9-diene derivatives, process for the preparation and use thereof, and pharmaceutical formulation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97200098.8 | 1997-01-15 | ||
EP97200098 | 1997-01-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998031702A1 true WO1998031702A1 (en) | 1998-07-23 |
Family
ID=8227931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/000377 WO1998031702A1 (en) | 1997-01-15 | 1998-01-13 | 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives |
Country Status (22)
Country | Link |
---|---|
US (1) | US6072068A (en) |
EP (1) | EP0973792B1 (en) |
JP (1) | JP2001508079A (en) |
KR (1) | KR20000070149A (en) |
CN (1) | CN1248262A (en) |
AR (1) | AR011409A1 (en) |
AT (1) | ATE248854T1 (en) |
AU (1) | AU736064B2 (en) |
BR (1) | BR9807079A (en) |
CA (1) | CA2277924A1 (en) |
DE (1) | DE69817792T2 (en) |
HU (1) | HUP0000901A3 (en) |
ID (1) | ID22228A (en) |
IL (1) | IL122740A (en) |
NO (1) | NO313386B1 (en) |
NZ (1) | NZ336790A (en) |
PL (1) | PL334518A1 (en) |
RU (1) | RU2187510C2 (en) |
TR (1) | TR199902367T2 (en) |
TW (1) | TW518339B (en) |
WO (1) | WO1998031702A1 (en) |
ZA (1) | ZA9884B (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000066522A1 (en) * | 1999-04-30 | 2000-11-09 | Pfizer Products Inc. | Glucocorticoid receptor modulators |
WO2001044267A1 (en) * | 1999-12-15 | 2001-06-21 | Jenapharm Gmbh & Co. Kg | 11-β-PHENYLESTRADIENE DERIVATIVES WITH FLUOROALKYL GROUPS IN THE AROMATIC SIDE CHAIN, PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS |
EP1201649A1 (en) * | 2000-10-28 | 2002-05-02 | Pfizer Products Inc. | Glucocorticoid receptor modulators |
EP1201655A2 (en) * | 2000-10-27 | 2002-05-02 | Pfizer Products Inc. | Process for the preparation of non-steroidal glucocorticoid receptor modulators |
EP1201660A1 (en) * | 2000-10-30 | 2002-05-02 | Pfizer Products Inc. | Glucocorticoid receptor modulators |
US7547714B2 (en) | 2007-02-02 | 2009-06-16 | Pfizer, Inc. | Tricyclic compounds, compositions, and methods |
US7713989B2 (en) | 2000-04-27 | 2010-05-11 | Dow Robert L | Glucocorticoid receptor modulators |
US9512169B2 (en) | 2012-07-10 | 2016-12-06 | Bayer Pharma Aktiengesellschaft | 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments |
WO2017112902A1 (en) * | 2015-12-23 | 2017-06-29 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
US9714266B2 (en) | 2013-02-21 | 2017-07-25 | Bayer Pharma Aktiengesellschaft | Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3) |
WO2018102369A1 (en) | 2016-11-30 | 2018-06-07 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
US10308676B2 (en) | 2015-09-25 | 2019-06-04 | Context Biopharma Inc. | Methods of making onapristone intermediates |
US10472387B2 (en) | 2016-10-07 | 2019-11-12 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
US10548905B2 (en) | 2015-12-15 | 2020-02-04 | Context Biopharma Inc. | Amorphous onapristone compositions and methods of making the same |
US10786461B2 (en) | 2014-11-17 | 2020-09-29 | Context Biopharma Inc. | Onapristone extended-release compositions and methods |
US11110103B2 (en) | 2015-12-23 | 2021-09-07 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
US11208432B2 (en) | 2015-12-23 | 2021-12-28 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
US20220072009A1 (en) * | 2018-12-28 | 2022-03-10 | Panda Consulting Llc | Short-acting selective glucocorticoid receptor modulators |
CN114456223A (en) * | 2022-01-24 | 2022-05-10 | 湖南科益新生物医药有限公司 | Method for synthesizing 3-ketal |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6740645B1 (en) * | 1999-09-03 | 2004-05-25 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties |
US7250408B2 (en) * | 2002-12-16 | 2007-07-31 | Bayer Schering Pharma Ag | Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility |
CN106397519A (en) * | 2016-08-30 | 2017-02-15 | 天津市中升挑战生物科技有限公司 | Preparation method of altrenogest |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3307143A1 (en) * | 1982-03-01 | 1983-09-08 | Roussel-Uclaf, 75007 Paris | NEW DERIVATIVES OF THE 3-KETO- (DELTA) -4,9,19-NOR-STEROIDS, THEIR PRODUCTION, THEIR USE AS MEDICINAL PRODUCTS, THE COMPOSITIONS CONTAINING THEM AND THE RECEIVED NEW INTERMEDIATE PRODUCTS |
EP0190759A2 (en) * | 1985-02-07 | 1986-08-13 | Schering Aktiengesellschaft | 11-Beta phenyl gonanes, their preparation and pharmaceutical compositions containing them |
-
1997
- 1997-12-24 IL IL12274097A patent/IL122740A/en active IP Right Grant
-
1998
- 1998-01-06 ZA ZA9884A patent/ZA9884B/en unknown
- 1998-01-12 TW TW087100392A patent/TW518339B/en not_active IP Right Cessation
- 1998-01-13 AT AT98906887T patent/ATE248854T1/en not_active IP Right Cessation
- 1998-01-13 US US09/341,603 patent/US6072068A/en not_active Expired - Fee Related
- 1998-01-13 HU HU0000901A patent/HUP0000901A3/en unknown
- 1998-01-13 PL PL98334518A patent/PL334518A1/en unknown
- 1998-01-13 JP JP53369598A patent/JP2001508079A/en active Pending
- 1998-01-13 NZ NZ336790A patent/NZ336790A/en unknown
- 1998-01-13 WO PCT/EP1998/000377 patent/WO1998031702A1/en not_active Application Discontinuation
- 1998-01-13 AU AU62935/98A patent/AU736064B2/en not_active Ceased
- 1998-01-13 CN CN98802618A patent/CN1248262A/en active Pending
- 1998-01-13 KR KR1019997006375A patent/KR20000070149A/en not_active Application Discontinuation
- 1998-01-13 DE DE69817792T patent/DE69817792T2/en not_active Expired - Fee Related
- 1998-01-13 EP EP98906887A patent/EP0973792B1/en not_active Expired - Lifetime
- 1998-01-13 TR TR1999/02367T patent/TR199902367T2/en unknown
- 1998-01-13 BR BR9807079-7A patent/BR9807079A/en not_active IP Right Cessation
- 1998-01-13 ID IDW990700A patent/ID22228A/en unknown
- 1998-01-13 RU RU99118008/04A patent/RU2187510C2/en not_active IP Right Cessation
- 1998-01-13 CA CA002277924A patent/CA2277924A1/en not_active Abandoned
- 1998-01-14 AR ARP980100151A patent/AR011409A1/en not_active Application Discontinuation
-
1999
- 1999-07-14 NO NO19993459A patent/NO313386B1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3307143A1 (en) * | 1982-03-01 | 1983-09-08 | Roussel-Uclaf, 75007 Paris | NEW DERIVATIVES OF THE 3-KETO- (DELTA) -4,9,19-NOR-STEROIDS, THEIR PRODUCTION, THEIR USE AS MEDICINAL PRODUCTS, THE COMPOSITIONS CONTAINING THEM AND THE RECEIVED NEW INTERMEDIATE PRODUCTS |
EP0190759A2 (en) * | 1985-02-07 | 1986-08-13 | Schering Aktiengesellschaft | 11-Beta phenyl gonanes, their preparation and pharmaceutical compositions containing them |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ304203B6 (en) * | 1999-04-30 | 2014-01-02 | Pfizer Products Inc. | Glucocorticoid receptor modulator and medicament containing thereof for the treatment of inflammatory disease |
AP1542A (en) * | 1999-04-30 | 2006-01-31 | Pfizer Prod Inc | Glucocorticoid receptor modulators. |
US6380223B1 (en) | 1999-04-30 | 2002-04-30 | Pfizer Inc. | Glucocorticoid receptor modulators |
US7166593B2 (en) | 1999-04-30 | 2007-01-23 | Pfizer, Inc. | Glucocorticoid receptor modulators |
EA007483B1 (en) * | 1999-04-30 | 2006-10-27 | Пфайзер Продактс Инк. | Use of glucocorticoid receptor modulators and glucocorticoid receptor agonists for preparing medicaments |
US6699893B2 (en) | 1999-04-30 | 2004-03-02 | Pfizer Inc | Glucocorticoid receptor modulators |
WO2000066522A1 (en) * | 1999-04-30 | 2000-11-09 | Pfizer Products Inc. | Glucocorticoid receptor modulators |
WO2001044267A1 (en) * | 1999-12-15 | 2001-06-21 | Jenapharm Gmbh & Co. Kg | 11-β-PHENYLESTRADIENE DERIVATIVES WITH FLUOROALKYL GROUPS IN THE AROMATIC SIDE CHAIN, PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS |
US7713989B2 (en) | 2000-04-27 | 2010-05-11 | Dow Robert L | Glucocorticoid receptor modulators |
EP1201655A3 (en) * | 2000-10-27 | 2002-06-26 | Pfizer Products Inc. | Process for the preparation of non-steroidal glucocorticoid receptor modulators |
EP1201655A2 (en) * | 2000-10-27 | 2002-05-02 | Pfizer Products Inc. | Process for the preparation of non-steroidal glucocorticoid receptor modulators |
EP1201649A1 (en) * | 2000-10-28 | 2002-05-02 | Pfizer Products Inc. | Glucocorticoid receptor modulators |
EP1201660A1 (en) * | 2000-10-30 | 2002-05-02 | Pfizer Products Inc. | Glucocorticoid receptor modulators |
US6852719B2 (en) | 2000-10-30 | 2005-02-08 | Pfizer Inc. | Glucocorticoid receptor modulators |
US7547714B2 (en) | 2007-02-02 | 2009-06-16 | Pfizer, Inc. | Tricyclic compounds, compositions, and methods |
US7598231B2 (en) | 2007-02-02 | 2009-10-06 | Pfizer, Inc. | Tricyclic compound, compositions, and methods |
US7786097B2 (en) | 2007-02-02 | 2010-08-31 | Pfizer Inc. | Tricyclic compounds, compositions and methods |
US8158660B2 (en) | 2007-02-02 | 2012-04-17 | Pfizer Inc. | Tricyclic compounds, compositions and methods |
US8445520B2 (en) | 2007-02-02 | 2013-05-21 | Pfizer Inc. | Tricyclic compounds, compositions, and methods |
US8901310B2 (en) | 2007-02-02 | 2014-12-02 | Pfizer Inc. | Tricyclic compounds, compositions, and methods |
US9512169B2 (en) | 2012-07-10 | 2016-12-06 | Bayer Pharma Aktiengesellschaft | 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments |
US9714266B2 (en) | 2013-02-21 | 2017-07-25 | Bayer Pharma Aktiengesellschaft | Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3) |
US10786461B2 (en) | 2014-11-17 | 2020-09-29 | Context Biopharma Inc. | Onapristone extended-release compositions and methods |
US11672762B2 (en) | 2014-11-17 | 2023-06-13 | Context Biopharma, Inc. | Onapristone extended-release compositions and methods |
US10308676B2 (en) | 2015-09-25 | 2019-06-04 | Context Biopharma Inc. | Methods of making onapristone intermediates |
US10548905B2 (en) | 2015-12-15 | 2020-02-04 | Context Biopharma Inc. | Amorphous onapristone compositions and methods of making the same |
US11124537B2 (en) | 2015-12-23 | 2021-09-21 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
AU2016377702B2 (en) * | 2015-12-23 | 2021-03-11 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
US11110103B2 (en) | 2015-12-23 | 2021-09-07 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
US11208432B2 (en) | 2015-12-23 | 2021-12-28 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
WO2017112902A1 (en) * | 2015-12-23 | 2017-06-29 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
US10723759B2 (en) | 2016-10-07 | 2020-07-28 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
US10472387B2 (en) | 2016-10-07 | 2019-11-12 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
US10836789B2 (en) | 2016-10-07 | 2020-11-17 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
WO2018102369A1 (en) | 2016-11-30 | 2018-06-07 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
US11613555B2 (en) | 2016-11-30 | 2023-03-28 | Context Biopharma, Inc. | Methods for onapristone synthesis dehydration and deprotection |
US20220072009A1 (en) * | 2018-12-28 | 2022-03-10 | Panda Consulting Llc | Short-acting selective glucocorticoid receptor modulators |
CN114456223A (en) * | 2022-01-24 | 2022-05-10 | 湖南科益新生物医药有限公司 | Method for synthesizing 3-ketal |
Also Published As
Publication number | Publication date |
---|---|
AU6293598A (en) | 1998-08-07 |
KR20000070149A (en) | 2000-11-25 |
BR9807079A (en) | 2000-04-18 |
NO313386B1 (en) | 2002-09-23 |
AU736064B2 (en) | 2001-07-26 |
TR199902367T2 (en) | 2000-04-21 |
US6072068A (en) | 2000-06-06 |
PL334518A1 (en) | 2000-02-28 |
HUP0000901A2 (en) | 2000-10-28 |
EP0973792A1 (en) | 2000-01-26 |
JP2001508079A (en) | 2001-06-19 |
DE69817792T2 (en) | 2004-07-01 |
NO993459L (en) | 1999-09-07 |
RU2187510C2 (en) | 2002-08-20 |
IL122740A (en) | 2003-09-17 |
ZA9884B (en) | 1998-07-08 |
NO993459D0 (en) | 1999-07-14 |
TW518339B (en) | 2003-01-21 |
NZ336790A (en) | 2000-06-23 |
DE69817792D1 (en) | 2003-10-09 |
HUP0000901A3 (en) | 2001-07-30 |
ID22228A (en) | 1999-09-23 |
CN1248262A (en) | 2000-03-22 |
AR011409A1 (en) | 2000-08-16 |
CA2277924A1 (en) | 1998-07-23 |
IL122740A0 (en) | 1998-08-16 |
EP0973792B1 (en) | 2003-09-03 |
ATE248854T1 (en) | 2003-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0973792B1 (en) | 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives | |
EP0763541B1 (en) | 11-(Substituted phenyl)-estra-4,9-diene derivatives | |
KR0161975B1 (en) | 11(beta)-substituted progesterone analogs | |
KR100287513B1 (en) | 17-spirofuran-3'-ylidene steroid | |
JP3814312B2 (en) | 11,1-bisphenyl-19-norpregnane derivative | |
KR101535686B1 (en) | Industrial method for the synthesis of 17-acetoxy-llβ-[4-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione and the key intermediates of the process | |
US5843933A (en) | 11β-aryl-4-estrenes, process for their production as well as their use as pharmaceutical agents | |
US5093507A (en) | 10β,11β-bridged steroids | |
JP3181589B2 (en) | 6,7-modified 11β-aryl-4-esterene | |
AU617442B2 (en) | Androst-4-ene derivatives | |
Peters et al. | Steroidal silicon side-chain analogs as potential antifertility agents | |
MXPA99006625A (en) | 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives | |
CZ253499A3 (en) | Derivatives of estra-4,9-diene and pharmaceutical preparation | |
MXPA96003476A (en) | Derivatives of 11- (substituted phenyl) -estra-4,9-di |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98802618.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AU BB BG BR BY CA CN CZ EE GE HU ID IS JP KG KP KR LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TR TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998906887 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2277924 Country of ref document: CA Ref document number: 2277924 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997006375 Country of ref document: KR Ref document number: 09341603 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 1998 533695 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 336790 Country of ref document: NZ Ref document number: PA/a/1999/006625 Country of ref document: MX Ref document number: PV1999-2534 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 62935/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999/02367 Country of ref document: TR |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-2534 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1998906887 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997006375 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 62935/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998906887 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1999-2534 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997006375 Country of ref document: KR |